Pharvaris NV (NASDAQ: PHVS)’s stock price has increased by 4.05 compared to its previous closing price of 17.30. However, the company has seen a 0.84% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-28 that ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation and ten abstracts for poster presentation at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany. Presentation details are as follows:
Is It Worth Investing in Pharvaris NV (NASDAQ: PHVS) Right Now?
The 36-month beta value for PHVS is at -3.10. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PHVS is 17.86M, and currently, shorts hold a 0.73% of that float. The average trading volume for PHVS on September 02, 2024 was 60.17K shares.
PHVS’s Market Performance
PHVS stock saw an increase of 0.84% in the past week, with a monthly gain of 12.92% and a quarterly increase of -5.06%. The volatility ratio for the week is 7.43%, and the volatility levels for the last 30 days are 8.41% for Pharvaris NV (PHVS). The simple moving average for the last 20 days is 2.05% for PHVS stock, with a simple moving average of -17.90% for the last 200 days.
Analysts’ Opinion of PHVS
Many brokerage firms have already submitted their reports for PHVS stocks, with Wedbush repeating the rating for PHVS by listing it as a “Outperform.” The predicted price for PHVS in the upcoming period, according to Wedbush is $27 based on the research report published on September 25, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see PHVS reach a price target of $34, previously predicting the price at $10. The rating they have provided for PHVS stocks is “Overweight” according to the report published on August 15th, 2023.
Bryan Garnier gave a rating of “Buy” to PHVS, setting the target price at $16 in the report published on October 05th of the previous year.
PHVS Trading at 1.11% from the 50-Day Moving Average
After a stumble in the market that brought PHVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.45% of loss for the given period.
Volatility was left at 8.41%, however, over the last 30 days, the volatility rate increased by 7.43%, as shares surge +11.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.22% lower at present.
During the last 5 trading sessions, PHVS rose by +0.84%, which changed the moving average for the period of 200-days by +6.82% in comparison to the 20-day moving average, which settled at $17.73. In addition, Pharvaris NV saw -35.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHVS starting from JOAN MARIE SCHMIDT, who proposed sale 836 shares at the price of $19.04 back on Aug 30 ’24. After this action, JOAN MARIE SCHMIDT now owns shares of Pharvaris NV, valued at $15,919 using the latest closing price.
JOAN MARIE SCHMIDT, the Officer of Pharvaris NV, proposed sale 900 shares at $19.04 during a trade that took place back on Aug 27 ’24, which means that JOAN MARIE SCHMIDT is holding shares at $17,136 based on the most recent closing price.
Stock Fundamentals for PHVS
The total capital return value is set at -0.36. Equity return is now at value -45.15, with -42.22 for asset returns.
Based on Pharvaris NV (PHVS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -696.61. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -5872.25.
Currently, EBITDA for the company is -94.67 million with net debt to EBITDA at 2.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.45.
Conclusion
In conclusion, Pharvaris NV (PHVS) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
